Invivyd, Inc. (IVVD)
0.6022
+0.04
(+6.96%)
USD |
NASDAQ |
Nov 09, 14:13
Invivyd Enterprise Value : 14.26M for Nov. 6, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 06, 2026 | 14.26M |
| November 05, 2026 | 20.74M |
| November 04, 2026 | 35.07M |
| November 03, 2026 | 19.71M |
| November 02, 2026 | 19.86M |
| October 30, 2026 | 19.77M |
| October 29, 2026 | 25.75M |
| October 28, 2026 | 30.06M |
| October 27, 2026 | 21.83M |
| October 26, 2026 | 21.98M |
| October 23, 2026 | 29.11M |
| October 22, 2026 | 28.14M |
| October 21, 2026 | 36.75M |
| October 20, 2026 | 35.95M |
| October 19, 2026 | 28.11M |
| October 16, 2026 | 30.65M |
| October 15, 2026 | 45.44M |
| October 14, 2026 | 27.46M |
| October 13, 2026 | 38.72M |
| October 12, 2026 | 46.77M |
| October 09, 2026 | 60.89M |
| October 08, 2026 | 54.76M |
| October 07, 2026 | 63.07M |
| October 06, 2026 | 86.00M |
| October 05, 2026 | 95.67M |
| Date | Value |
|---|---|
| October 02, 2026 | 90.63M |
| October 01, 2026 | 88.98M |
| September 30, 2026 | 104.78M |
| September 29, 2026 | 98.88M |
| September 28, 2026 | 128.33M |
| September 25, 2026 | 123.67M |
| September 24, 2026 | 117.51M |
| September 23, 2026 | 120.40M |
| September 22, 2026 | 132.45M |
| September 21, 2026 | 148.96M |
| September 18, 2026 | 70.94M |
| September 17, 2026 | 68.26M |
| September 16, 2026 | 85.68M |
| September 15, 2026 | 92.96M |
| September 14, 2026 | 111.17M |
| September 11, 2026 | 79.84M |
| September 10, 2026 | 77.01M |
| September 09, 2026 | 83.32M |
| September 08, 2026 | 91.72M |
| September 04, 2026 | 91.78M |
| September 03, 2026 | 94.43M |
| September 02, 2026 | 85.29M |
| September 01, 2026 | 107.67M |
| August 31, 2026 | 129.77M |
| August 28, 2026 | 132.60M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Lineage Cell Therapeutics, Inc. | 208.32M |
| Armata Pharmaceuticals, Inc. | 420.38M |
| Voyager Therapeutics, Inc. | 39.65M |
| Black Diamond Therapeutics, Inc. | 6.133M |
| Elicio Therapeutics, Inc. | 25.83M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -44.39M |
| Revenue (Quarterly) | 14.28M |
| Total Expenses (Quarterly) | 58.68M |
| EPS Diluted (Quarterly) | -0.1385 |
| Gross Profit Margin (Quarterly) | 86.62% |
| Profit Margin (Quarterly) | -310.8% |
| Earnings Yield | -61.94% |
| Normalized Earnings Yield | -61.94 |